Vanguard Group
UBX

Vanguard Group’s Unity Biotechnology UBX Stock Holding History

Vanguard Group’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-673,090
Closed -$256K – 4429
2025
Q2 		$256K Hold
673,090
– – ﹤0.01% 4044
2025
Q1 		$700K Buy
673,090
+82,320
+14% +$149K ﹤0.01% 3809
2024
Q4 		$577K Hold
590,770
– – ﹤0.01% 3908
2024
Q3 		$868K Hold
590,770
– – ﹤0.01% 3817
2024
Q2 		$798K Buy
590,770
+33,417
+6% +$50.7K ﹤0.01% 3869
2024
Q1 		$914K Sell
557,353
-4,249
-0.8% -$7.37K ﹤0.01% 3845
2023
Q4 		$1.08M Hold
561,602
– – ﹤0.01% 3800
2023
Q3 		$1.35M Sell
561,602
-1,356
-0.2% -$3.59K ﹤0.01% 3730
2023
Q2 		$1.44M Buy
562,958
+39,034
+7% +$103K ﹤0.01% 3779
2023
Q1 		$854K Buy
523,924
+80,100
+18% +$321K ﹤0.01% 3972
2022
Q4 		$1.22M Buy
443,824
+98
+0% +$285 ﹤0.01% 3844
2022
Q3 		$1.75M Buy
443,726
+315,559
+246% +$1.99M ﹤0.01% 3796
2022
Q2 		$723K Buy
128,167
+15,647
+14% +$131K ﹤0.01% 4186
2022
Q1 		$1.26M Sell
112,520
-65,361
-37% -$733K ﹤0.01% 4141
2021
Q4 		$2.6M Buy
177,881
+36,943
+26% +$807K ﹤0.01% 3946
2021
Q3 		$4.23M Sell
140,938
-855
-0.6% -$30.2K ﹤0.01% 3765
2021
Q2 		$6.58M Sell
141,793
-16,510
-10% -$795K ﹤0.01% 3438
2021
Q1 		$9.5M Buy
158,303
+1,054
+0.7% +$71.9K ﹤0.01% 3170
2020
Q4 		$8.24M Sell
157,249
-3,720
-2% -$179K ﹤0.01% 3092
2020
Q3 		$5.57M Buy
160,969
+16,569
+11% +$1.05M ﹤0.01% 3100
2020
Q2 		$12.5M Buy
144,400
+31,440
+28% +$2.33M ﹤0.01% 2653
2020
Q1 		$6.55M Buy
112,960
+13,079
+13% +$824K ﹤0.01% 2826
2019
Q4 		$7.2M Buy
99,881
+377
+0.4% +$26.6K ﹤0.01% 3014
2019
Q3 		$6.07M Buy
99,504
+34,784
+54% +$2.46M ﹤0.01% 3063
2019
Q2 		$6.15M Sell
64,720
-12,631
-16% -$1.07M ﹤0.01% 3093
2019
Q1 		$6.27M Buy
77,351
+4,999
+7% +$567K ﹤0.01% 3055
2018
Q4 		$11.8M Buy
72,352
+49,781
+221% +$6.61M ﹤0.01% 2690
2018
Q3 		$3.68M Buy
22,571
+11,318
+101% +$1.86M ﹤0.01% 3336
2018
Q2 		$1.7M Buy
+11,253
New +$1.64M ﹤0.01% 3549

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Vanguard Group's UBX Position: Q3 2025 in Review

Vanguard Group sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 673,090 shares — an estimated $256K sold.

Vanguard Group first reported a position in UBX in Q2 2018 and held it in 29 quarters. The position peaked at $12.5M in Q2 2020. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

  • Vanguard Group reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Vanguard Group sold 673,090 Unity Biotechnology shares in Q3 2025, an estimated $256K.
  • Vanguard Group first reported a position in Unity Biotechnology in Q2 2018 and held it in 29 quarters.
  • Vanguard Group's Unity Biotechnology position peaked at $12.5M in Q2 2020.
  • 6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on Vanguard Group's 13F filing for Q3 2025, filed 7 Nov 2025.